Capricor Therapeutics Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Capricor Therapeutics de 59.4% y 39.4% respectivamente, mientras que el BPA crecerá en un 61.7% al año.

Información clave

66.2%

Tasa de crecimiento de los beneficios

66.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.8%
Tasa de crecimiento de los ingresos	39.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	16 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

Feb 01

We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Oct 14

Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result

Sep 25

Capricor Therapeutics slumps 9% on $75M stock offering

Jun 21

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

May 16

When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?

Mar 13

Capricor signs intellectual property license for COVID-19 serology test platform

Feb 01

Capricor and Lonza tie up in DMD development

Jan 12

Dosing underway in Capricor Therapeutics' mid-stage CAP-1002 study in COVID-19

Nov 24

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:CAPR - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	108	15	-11	N/A	5
12/31/2025	79	-5	-44	N/A	5
12/31/2024	27	-34	-9	N/A	4
3/31/2024	27	-24	N/A	N/A	N/A
12/31/2023	25	-22	-28	-26	N/A
9/30/2023	14	-29	-23	-21	N/A
6/30/2023	9	-29	-21	-18	N/A
3/31/2023	6	-29	-18	-15	N/A
12/31/2022	3	-29	2	5	N/A
9/30/2022	2	-27	4	6	N/A
6/30/2022	N/A	-25	7	9	N/A
3/31/2022	0	-23	9	11	N/A
12/31/2021	0	-20	-18	-17	N/A
9/30/2021	0	-18	-16	-15	N/A
6/30/2021	0	-18	-15	-15	N/A
3/31/2021	0	-17	-13	-12	N/A
12/31/2020	0	-14	-11	-10	N/A
9/30/2020	0	-11	-8	-8	N/A
6/30/2020	1	-9	-7	-7	N/A
3/31/2020	1	-7	-6	-6	N/A
12/31/2019	1	-8	-7	-7	N/A
9/30/2019	1	-9	-9	-9	N/A
6/30/2019	2	-12	-10	-10	N/A
3/31/2019	2	-14	-12	-12	N/A
12/31/2018	2	-15	-14	-14	N/A
9/30/2018	1	0	-13	-13	N/A
6/30/2018	2	2	-13	-13	N/A
3/31/2018	2	2	-13	-13	N/A
12/31/2017	3	2	N/A	-14	N/A
9/30/2017	3	-14	N/A	-15	N/A
6/30/2017	4	-17	N/A	-14	N/A
3/31/2017	4	-18	N/A	-15	N/A
12/31/2016	4	-19	N/A	-14	N/A
9/30/2016	4	-18	N/A	-15	N/A
6/30/2016	5	-15	N/A	-16	N/A
3/31/2016	5	-14	N/A	-13	N/A
12/31/2015	6	-13	N/A	-11	N/A
9/30/2015	6	-11	N/A	-9	N/A
6/30/2015	6	-10	N/A	-8	N/A
3/31/2015	6	-8	N/A	-12	N/A
12/31/2014	5	-6	N/A	1	N/A
9/30/2014	3	-9	N/A	3	N/A
6/30/2014	2	-9	N/A	1	N/A
3/31/2014	1	-9	N/A	6	N/A
12/31/2013	1	-9	N/A	-6	N/A
9/30/2013	1	-5	N/A	-7	N/A
6/30/2013	2	-4	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CAPR sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que CAPR sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que CAPR sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (39.4% al año) de CAPR crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (39.4% al año) de CAPR crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CAPR se prevé que sea elevada dentro de 3 años.

Capricor Therapeutics Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast breakeven date pushed back to 2026

Consensus revenue estimates increase by 41%

Consensus revenue estimates fall by 51%

Consensus revenue estimates increase by 86%

Forecast breakeven date moved forward to 2024

Consensus revenue estimates increase by 27%

Recent updates

Forecast breakeven date pushed back to 2026

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Capricor Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc., Annual General Meeting, May 14, 2024

Consensus revenue estimates increase by 41%

Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Capricor Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Capricor Therapeutics Announces Continuation of Phase 3 Hope-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

New major risk - Financial position

Capricor Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Consensus revenue estimates fall by 51%

New minor risk - Market cap size

Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. Appoints Michael Kelliher to Its Board of Directors

New minor risk - Share price stability

Consensus revenue estimates increase by 86%

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Forecast breakeven date moved forward to 2024

Capricor Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insufficient new directors

Capricor Therapeutics Announces the Appointment of Philip J. Gotwals to Its Board of Directors

Capricor Therapeutics, Inc Announces Board Changes

Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

Consensus revenue estimates increase by 27%

Forecast breakeven date moved forward to 2024

Capricor Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Chief Business Officer exercised options and sold US$51k worth of stock

Independent Director notifies of intention to sell stock

Forecast breakeven date moved forward to 2024

Capricor Therapeutics, Inc. Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients

Forecast to breakeven in 2025

Now 26% undervalued after recent price drop

Consensus revenue estimates increase by 146%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Forecast to breakeven in 2024

Now 20% undervalued after recent price drop

Capricor Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Capricor Therapeutics, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Capricor Therapeutics, Inc. Announces First Patient Dose in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

Independent Director recently sold US$79k worth of stock

Capricor Therapeutics, Inc. Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with Cap-1002 in Hope-2 Open Label Extension Study

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

Forecast to breakeven in 2023

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Capricor Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target increased to US$15.00

Insufficient new directors

Capricor Therapeutics, Inc., Annual General Meeting, Jun 03, 2022

Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory Inspire Trial in Severe Hospitalized Covid-19 Patients

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Capricor Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

Executive Chairman of the Board exercised options and sold US$121k worth of stock

Capricor Therapeutics, Inc. Announces Key Updates on Its Vaccine and Therapeutic Programs for COVID-19

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.20 loss in 3Q 2020)

We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth